Day 2 Options to improve access to safe plasma protein products in LMIC
Chair(s):
Jay Epstein
,
Jay Epstein
Affiliations:
Jean-Claude Faber
Jean-Claude Faber
Affiliations:
Speaker(s):
Giuliano Grazzini
,
Giuliano Grazzini
Affiliations:
Pierre Tiberghien
,
Pierre Tiberghien
Affiliations:
Jeffrey McCullough
,
Jeffrey McCullough
Affiliations:
Hans Vermeij
,
Hans Vermeij
Affiliations:
Stefan Reichenberg
,
Stefan Reichenberg
Affiliations:
Salwa Hindawi
,
Salwa Hindawi
Affiliations:
Magdy El Ekiaby
,
Magdy El Ekiaby
Affiliations:
Johannes Bluemel
Johannes Bluemel
Affiliations:
ISBT Education. Faber J. 09/23/21; 344778 Topic: Blood components and products
Jay Epstein
Jean-Claude Faber
Giuliano Grazzini
Pierre Tiberghien
Jeffrey McCullough
Hans Vermeij
Stefan Reichenberg
Salwa Hindawi
Magdy El Ekiaby
Johannes Bluemel
About this activity
This recording captures the first session of Day 2 of the workshop Stepwise Access to Safe Plasma Proteins in Resource-Constrained Countries: Local Production & Pathways to Fractionation, which was held online on Wednesday September 22, 2021.

Day 2 Session 1: Options to improve access to safe plasma protein products in LMIC:
Moderators: Jean-Claude Faber (Luxembourg - ISBT WP GBS) and Jay Epstein (USA - ISBT WP GBS)
- Giuliano Grazzini, Italy - FIODS: Recruitment and retention of safe Donors 
Pierre Tiberghien, France - EFS: Quarantine of plasma as a means to reduce the risk of transfusion-transmitted infection: logistics and feasibility 
- Technologies for pathogen reduction (PR) of single-donor or mini-pools of plasma, cryoprecipitate, and immunoglobulins, experience from suppliers and users:
  • Strategies to move safe plasma products into low resource areas: overview and experience with Riboflavin/UV (Jeffrey McCullough, USA)
  • Psoralen/UVA (Hans Vermeij, Brazil - Cerus)
  • Methylene blue/light (Stefan Reichenberg, Germany - Macopharma)
  • Pathogen reduction of COVID-19 convalescent plasma (Salwa Hindawi, Saudi Arabia - King Abdulaziz University)
  • Mini-pool solvent/detergent of plasma, cryoprecipitate & caprylic acid fractionation of immunoglobulins (VIPS) (Magdy El-Ekiaby, Egypt, Shabrawishi Hospital)
- Johannes Bluemel, Germany - PEI: Viral safety of plasma derived components
- Discussion/Q&A

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies